jakarta2 update: fedratinib in mf patients previously treated with ruxolitinib
Published 4 years ago • 67 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:27
real-world use of fedratinib in patients with mf who have failed on ruxolitinib
-
2:41
jakarta & jakarta2: pfs and os with fedratinib in myelofibrosis
-
1:27
jakarta and jakarta2: os and pfs analysis of fedratinib in myelofibrosis
-
3:44
phase ii study update of navtemadlin in patients with myelofibrosis r/r to ruxolitinib
-
2:00
the role of fedratinib in 2024 and beyond
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
1:42
berapa biaya pengobatan tof? - dr marhisham che mood - ijn
-
5:10
what are the treatment options for myelofibrosis?
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
2:03
preliminary results of a phase ii study of fedratinib in patients with mds/mpn and cnl
-
1:25
the current approach to managing patients with prefibrotic pmf
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
1:54
jakarta-2 reanalysis demonstrates activity with fedratinib in mf after ruxolitinib failure
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
3:43
updated results from manifest arm 2: pelabresib as add-on to ruxolitinib in myelofibrosis
-
1:16
using rwd to evaluate the use of fedratinib as a potential bridge to hsct in patients with mf
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
5:10
fedratinib in mf: jakarta2 and freedom trials